Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. - Wikidata - awgldk - TriplyDB

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

http://www.wikidata.org/entity/Q46696489

about

Fostering Competence in Medicines Development: The IFAPP Perspective Dynamic Assessment of Value During High-Cost Cancer Treatment: A Response to American Society of Clinical Oncology and European Society of Medical Oncology.New Expensive Anticancer Agents: Which Role Is Played by Quality-Adjusted Life-Years in the Selection of a Specific Treatment?Demonstrating the value of medicines: evolution of value equation and stakeholder perception of uncertainties.Addressing Patients' Priorities as a Strategy to Improve Value.Defining Health Across the Cancer Continuum.Application of the American Society of Clinical Oncology frameworks to compare tyrosine kinase inhibitors used in first line treatment of metastatic renal cell carcinoma: Had we solved the mystery?Dynamic value assessments in oncology supported by the PACE Continuous Innovation Indicators.Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations.Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.Evaluating Frameworks That Provide Value Measures for Health Care Interventions.Meaningful endpoints for therapies approved for hematologic malignancies.Economics of ramucirumab for metastatic colorectal cancer.The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations.Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.Targeted therapies for renal cell carcinoma.Do Patients and Oncologists Discuss the Cost of Cancer Treatment? An Observational Study of Clinical Interactions Between African American Patients and Their Oncologists.Another disappointing result, but how good is it?Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry.Overview on Patient Centricity in Cancer Care.Cancer drugs in LMICs: cheap but unaffordable.How Useful Are International Treatment Guidelines in Low- and Middle-Income Countries?Targeting the value of targeted therapy.Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care.Diffusion of Bevacizumab Across Oncology Practices: An Observational Study.Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review.Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.Estimating global treatment toxicity burden from adverse-event data.Patient value: Perspectives from the advocacy community.Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.The cost and value of glioblastoma therapy.Hans Christian Andersen and the Value of New Cancer Treatments.Re-Aligning the ASCO and ESMO Clinical Benefit Frameworks for Modern Cancer Therapies.Clinical pathways in chronic lymphocytic leukemia: Challenges and solutions.At least, do no harm.Defining Value: The Need for a Longer, Broader View.Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'.Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape.Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.

P2860

Q28821990-5E04E12E-F77E-43B4-83AC-CBB62D4B91FF Q33756769-A3E3D005-0F5F-4672-8070-9D0854FF2EBA Q33859608-5C34EDFB-0434-499A-B757-397765604A6A Q37116554-BFF05CEB-2B2A-4D93-BB90-8379DD6E6FDC Q37535993-50D5F97A-D699-49B3-8D2E-D2F45B914BA1 Q37705533-8AFC30FA-939E-453B-A6C5-82A99F4AF162 Q38598277-53F9E34C-212F-4B5E-BEBF-28B34B2A4E51 Q38651603-D731C1AC-0664-4317-9A53-66C1470B2E40 Q38652111-96EBEC5E-A90E-4574-81F0-B30AD2C91092 Q38811530-C2FBAD54-2EBF-4A31-A5C1-06BC21BBA1A1 Q38879397-BCE99557-AB7C-4662-B787-FF3F11930950 Q38942315-EFB60E6B-AAA9-4083-ADF9-DE486E853836 Q38950082-5E352B55-F4F3-4803-A6E3-4DD918ED25AB Q39003764-F825D944-5888-466E-B844-BB4299458999 Q39161081-4D681EDF-1C20-474E-8B13-F2DA94D89238 Q39270072-6117D2E4-9D46-4852-AA11-F308228C7134 Q39425380-F4E2CC1A-1F30-4E6D-98F8-EFD88239C49B Q40427977-32402F7E-218E-4099-8517-FD254022B52E Q42332732-6EA2EF36-F0F4-49D4-B883-8D9230F29C21 Q42366785-C4721665-1096-4254-8443-E3012EC6FCE3 Q42373477-8FE8BFCE-2728-41AF-BC6C-E8CEBBF14AD4 Q45362505-214C8179-4AFC-4397-8A79-BF8F86068D6D Q46425497-FAEF49FE-E81B-44EE-8C1B-D79B607E94F3 Q47120188-24D3C332-166C-4753-8001-CE8344817AC1 Q47236231-75FDA0C3-1C93-4DDF-9599-4F9535FFBEF0 Q47405286-C3722A22-BEE2-4DFC-95F6-0906AAE508EE Q47447980-1C43404E-05C2-4D92-BB05-588E679FA86E Q47552083-0F528482-56E8-41F3-90E2-69F8038D13B5 Q47641160-2A25BD10-6F79-42A9-A2E0-C3C6B0E56F6E Q47682226-A61911AD-D21E-4390-800F-EDF54612827E Q47890295-D38CCA07-7A97-4305-A3C7-52ECF51715B8 Q48204740-72D03D1F-6713-4F84-AA76-C6F152C91C26 Q49824552-22F7125B-EF36-4558-B226-7CB35EE03A9B Q50121296-B01C3EFE-041E-4F11-A900-160FCC3D5BE9 Q51371549-5212CB90-188A-4FD3-AF0D-5F9CC3B8D82A Q53105467-936A9DFE-78D6-489F-92A1-1FC874644CC4 Q53404628-4CB811B5-955A-488F-89F6-1D8F49A90A67 Q53830964-27F5ED53-DAB5-48ED-9700-6990613D8172 Q54974210-EA02535B-BD39-4697-AD12-96F76324558E Q54981288-C18DC077-2484-463C-B7EE-A9E3EB79F76B

P2860

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

http://www.wikidata.org/entity/Q46696489

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Updating the American Society ...... Response to Comments Received.

@en

Updating the American Society ...... Response to Comments Received.

@nl

type

label

Updating the American Society ...... Response to Comments Received.

@en

Updating the American Society ...... Response to Comments Received.

@nl

prefLabel

Updating the American Society ...... Response to Comments Received.

@en

Updating the American Society ...... Response to Comments Received.

@nl

P1433

Q46696489-26F0AECC-1C67-44FB-A91B-3C47E4561F74

P1476

Q46696489-9D46293E-F4D9-4B6D-ADB7-70BC059A7C6B

P2093

Q46696489-379677E1-D527-439F-925B-E1E1EBA4A827

Q46696489-39FAD466-9DE8-4DE3-98C1-A1D5B1310C30

Q46696489-41F8C5CC-19EB-4C29-BB53-CA6389E11BC8

Q46696489-4AA048CA-B551-45A1-B6C2-3B0DC5B8EF75

Q46696489-536427F8-A3B5-4663-91CF-3011398B89B5

Q46696489-5691A142-D0E2-4407-BBA9-ACA08968F8F1

Q46696489-5AEA1AF8-9A86-49CC-8768-02BDCD8D5377

Q46696489-6C99EC8A-E080-4634-B210-55C8F3B5401D

Q46696489-716FD170-5004-44B4-8ED3-16C0232B5630

Q46696489-8AD9FC9E-0E98-496A-BB5E-359A122D21CC

P304

Q46696489-B2B013F5-4C5A-407B-A917-03E71FBD23E0

P31

Q46696489-3D1BBAFE-B72D-41FC-8E41-81AB597F06D1

P356

Q46696489-B4F433D2-7254-499A-8013-BBF5BF9B88CD

P407

Q46696489-0141B7A5-4699-4E44-8B9E-7F823F8F2D39

P433

Q46696489-356CE3A1-7478-488D-B99B-D227D3BB582D

P478

Q46696489-ABC14F9F-75A0-415C-84B6-5E5E43892D47

P50

Q46696489-7533B15B-B45E-4A84-8CE5-D58A500D6BB4

P577

Q46696489-FF110638-C09B-4BA2-9F08-DD8BFD8DE329

P698

Q46696489-DDB587B9-6067-4A14-A003-D30B4A56517D

P356

JCO.2016.68.2518

P1433

Journal of Clinical Oncology

P1476

Updating the American Society ...... Response to Comments Received

@en

P2093

Adam P Dicker

http://www.w3.org/2001/XMLSchema#string

Blase Polite

http://www.w3.org/2001/XMLSchema#string

Clifford A Hudis

http://www.w3.org/2001/XMLSchema#string

Dana S Wollins

http://www.w3.org/2001/XMLSchema#string

Deborah Schrag

http://www.w3.org/2001/XMLSchema#string

Derek Raghavan

http://www.w3.org/2001/XMLSchema#string

Douglas W Blayney

http://www.w3.org/2001/XMLSchema#string

Gary H Lyman

http://www.w3.org/2001/XMLSchema#string

Gregory Rossi

http://www.w3.org/2001/XMLSchema#string

J Russell Hoverman

http://www.w3.org/2001/XMLSchema#string

P304

2925-2934

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2016.68.2518

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

Thomas J. Smith

P577

2016-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27247218

http://www.w3.org/2001/XMLSchema#string